4.4 Naloxone Access, Standing Orders & Overdose Prevention

4.4 Naloxone Access, Standing Orders & Overdose Prevention

[!NOTE] Core Legal Authorities: Opioid antidote distribution and overdose response in New Jersey are established under the Overdose Prevention Act (N.J.S.A. 24:6J-1 et seq.), co-prescribing mandates under N.J.S.A. 45:9-22.19b, New Jersey State Board of Pharmacy rules (N.J.A.C. 13:39-7.1), and the Statewide Standing Order for Opioid Antidotes issued by the Commissioner of Health.

To combat the mortality associated with synthetic opioids and prescription narcotic misuse, New Jersey has eliminated legal and procedural barriers to opioid antagonist distribution. Under New Jersey law, naloxone is treated as a universal public-health rescue tool, empowering pharmacists to dispense life-saving antagonists directly to patients, family members, first responders, and community entities without an individual physician prescription.

---

The New Jersey Statewide Standing Order

Under N.J.S.A. 24:6J-4, the Commissioner of the New Jersey Department of Health maintains a Statewide Standing Order for Opioid Antidotes that operates as an open, universal prescription covering all licensed pharmacists practicing in the state.

+---------------------------------------------------------------------------------------------------+
|                         NEW JERSEY NALOXONE STANDING ORDER FRAMEWORK                              |
+----------------------------+----------------------------------------------------------------------+
| Statutory Dimension        | Operational Mechanism / Rule                                         |
+----------------------------+----------------------------------------------------------------------+
| Dispensing Authority       | Any licensed New Jersey pharmacist acting under Statewide Standing   |
|                            | Order; no individual collaborative practice agreement required       |
+----------------------------+----------------------------------------------------------------------+
| Eligible Recipients        | Any individual at risk, family member, friend, caregiver, first      |
|                            | responder, school personnel, or entity (Third-Party Dispensing)       |
+----------------------------+----------------------------------------------------------------------+
| Mandatory Co-Prescribing   | SUD history, OR daily dose > 90 MME, OR current C-III/IV benzo Rx    |
+----------------------------+----------------------------------------------------------------------+
| Legal Immunities           | Full civil liability, criminal prosecution, and administrative Board |
|                            | licensing immunity for good-faith dispensing or administration       |
+----------------------------+----------------------------------------------------------------------+
| Good Samaritan Shield      | Immunity from arrest, charge, and prosecution for simple drug        |
|                            | possession when summoning 911 emergency medical assistance           |
+----------------------------+----------------------------------------------------------------------+

Key Operational Protocols Under the Standing Order

1. No Patient-Specific Prescription Required: A pharmacist does not need to contact a physician or obtain an individualized prescription to dispense naloxone. The standing order itself serves as the legal prescription.
2. Universal Pharmacist Inclusion: Every New Jersey licensed pharmacist practicing in a registered retail pharmacy or institutional setting is authorized to dispense under the standing order; pharmacists do not need to register individually with the state or enter into separate physician agreements.
3. Approved Antidote Formulations: The standing order authorizes multiple FDA-approved opioid antagonist formulations, including:
   • Naloxone nasal spray 4 mg (Narcan and generic equivalents)
   • Naloxone nasal spray 8 mg (Kloxxado)
   • Naloxone auto-injectors (Evzio / generic auto-injectors)
   • Naloxone pre-filled syringes for intramuscular injection with atomizers
   • Nalmefene nasal spray (Opvee)

---

Mandatory Co-Prescribing & Offering Thresholds

Under New Jersey law (N.J.S.A. 45:9-22.19b) and administrative prescribing rules, healthcare practitioners and dispensing pharmacists must proactively address overdose risk through mandatory co-prescribing and offering requirements.

The co-prescribing mandate is codified at N.J.S.A. 24:21-15.2(j) — the same section that carries the five-day acute-pain limit. When a health care practitioner issues a prescription for an opioid drug that is a controlled dangerous substance, the practitioner shall additionally issue the patient a prescription for an opioid antidote if any of the following three conditions is present:

1. History of Substance Use Disorder:
   • The patient has a history of substance use disorder. This is a standalone trigger and does not depend on dose.
2. High-Dose Opioid Therapy (the ">90 MME" Rule):
   • The prescription for the opioid drug is for a daily dose of more than 90 morphine milligram equivalents.
   • Read the operator carefully. The statute says more than 90 MME, not "90 or more." A regimen calculating to exactly 90 MME/day does not trigger the mandate on dose alone; 91 MME/day does. Item writers build distractors on precisely this boundary.
   • Example Calculation: Oxycodone carries an MME conversion factor of 1.5. Oxycodone 20 mg three times daily is 60 mg/day × 1.5 = 90 MME/day — exactly at the line, and therefore not over it. Increase the regimen to oxycodone 25 mg three times daily (75 mg × 1.5 = 112.5 MME/day) and the mandate applies.
3. Concurrent Benzodiazepine Prescription:
   • The patient holds a current, valid prescription for a benzodiazepine drug that is a Schedule III or Schedule IV controlled dangerous substance. Note both qualifiers: the benzodiazepine prescription must be current and valid rather than merely a historical fill, and the statute reaches C-III/C-IV benzodiazepines.
   • Rationale: Combining opioids and benzodiazepines dramatically increases the risk of fatal respiratory depression.

The One-Per-Year Ceiling

Under N.J.S.A. 24:21-15.2(j)(2), a practitioner is not required to issue more than one opioid-antidote prescription to a patient per year. A prescriber who already co-prescribed naloxone for this patient four months ago has satisfied the mandate. Subsection (j)(3) preserves the practitioner's discretion to issue additional antidote prescriptions on the patient's request or when there is a clinical or practical need.

[!IMPORTANT] The Triggers on the MPJE: Work the three conditions as a disjunction and check the arithmetic before answering. Morphine Sulfate ER 45 mg twice daily is 90 mg/day × an MME factor of 1 = 90 MME — exactly at the line, not over it, so dose alone does not trigger the mandate. Hydrocodone/APAP 10/325 mg for a patient holding a current Clonazepam 1 mg prescription does trigger it, because clonazepam is a Schedule IV benzodiazepine. And a modest hydrocodone prescription for a patient with a documented history of substance use disorder triggers it on condition (1) no matter how low the dose. Independent of the statutory mandate, offering naloxone and counseling on its use remains sound practice in all of these situations — the point of the exam question is which fact pattern makes it legally compulsory.

---

Third-Party Dispensing Rights

Under N.J.S.A. 24:6J-4(a)(2), New Jersey law explicitly authorizes third-party dispensing:

• A pharmacist may legally dispense an opioid antidote to a third party—defined as an individual who is not at personal risk of an overdose, but who is in a position to assist an individual who may experience an overdose.
• Eligible third-party recipients include family members, friends, domestic partners, roommates, social workers, school personnel, and community outreach advocates.
• Pharmacy Processing: When processing a third-party dispense under the standing order, the pharmacy profile and prescription record are established under the name of the requesting individual (the third party), not the anonymous or potential overdose victim.

---

Broad Statutory Immunity Protections

To ensure that fear of liability does not impede overdose intervention, the New Jersey Overdose Prevention Act establishes robust, multi-tiered statutory immunity for pharmacists, prescribers, and lay responders (N.J.S.A. 24:6J-4 & 24:6J-5):

+---------------------------------------------------------------------------------------------------+
|                         NEW JERSEY OVERDOSE PREVENTION ACT IMMUNITY TIERS                         |
+------------------------+--------------------------------------------------------------------------+
| Immunity Category      | Scope of Legal Protection                                                |
+------------------------+--------------------------------------------------------------------------+
| Civil Immunity         | Complete protection against civil tort liability, personal injury,       |
|                        | or medical malpractice lawsuits resulting from dispensing or administering|
+------------------------+--------------------------------------------------------------------------+
| Criminal Immunity      | Absolute immunity from criminal arrest, prosecution, or penal charges    |
|                        | for the unlawful practice of medicine or illegal drug distribution       |
+------------------------+--------------------------------------------------------------------------+
| Administrative Board   | Complete protection against professional licensing disciplinary action,  |
| Disciplinary Immunity  | license suspension, fines, or reprimands by the Board of Pharmacy       |
+------------------------+--------------------------------------------------------------------------+

Prerequisite: The only condition required to secure statutory immunity is that the healthcare professional or lay individual acted in good faith and with reasonable care.

Overdose Good Samaritan Legal Protections

Under N.J.S.A. 2C:35-30, New Jersey provides Good Samaritan criminal immunity to encourage bystanders to call 911 immediately during an overdose:

• Any individual who, in good faith, summons emergency medical assistance for a person experiencing an overdose—as well as the person experiencing the overdose—is immune from arrest, charge, prosecution, or revocation of parole/probation for:
  1. Simple possession or use of any controlled dangerous substance (including heroin, fentanyl, cocaine, or unprescribed opioids).
  2. Possession of hypodermic needles, syringes, or drug paraphernalia.
• Limitation: The Good Samaritan shield does not protect individuals from arrest or prosecution for major crimes, such as drug trafficking, maintaining a CDS production facility, distribution, or violent felonies.

---

Clinical Counseling & Patient Education Protocol

When dispensing an opioid antidote under the standing order or pursuant to a prescription, the pharmacist must ensure the recipient receives comprehensive, actionable counseling covering five essential clinical domains:

+---------------------------------------------------------------------------------------------------+
|                         MANDATORY OVERDOSE RECOGNITION & RESPONSE STEPS                           |
+---------------------------------------------------------------------------------------------------+
| STEP 1: RECOGNIZE OVERDOSE                                                                        |
| Look for the Opioid Overdose Triad: Pinpoint Pupils (Miosis), Severe Respiratory Depression,      |
| and Unresponsiveness. Check for cyanosis (blue lips/fingernails) and 'death rattle' sounds.      |
+---------------------------------------------------------------------------------------------------+
| STEP 2: ADMINISTER NALOXONE NASAL SPRAY                                                           |
| Peel package open; place nozzle in one nostril; press plunger firmly. DO NOT prime or test.       |
+---------------------------------------------------------------------------------------------------+
| STEP 3: CALL 911 IMMEDIATELY                                                                      |
| Inform dispatch: 'Someone is unresponsive and not breathing.' Summon advanced life support.       |
+---------------------------------------------------------------------------------------------------+
| STEP 4: RESCUE BREATHING & RECOVERY POSITION                                                      |
| Provide rescue breaths if trained; place patient on side in recovery position to prevent choking. |
+---------------------------------------------------------------------------------------------------+
| STEP 5: EVALUATE & REPEAT IN 2 TO 3 MINUTES                                                       |
| If patient does not wake up or resume normal breathing within 2–3 minutes, administer 2nd dose     |
| into the alternate nostril using a fresh device.                                                  |
+---------------------------------------------------------------------------------------------------+

1. Identifying the Clinical Signs of Opioid Overdose

• The Classic Opioid Triad: (1) Respiratory depression (slow, irregular, or absent breathing, < 8 breaths/min), (2) Pinpoint pupils (extreme miosis), and (3) Stupor, coma, or profound unresponsiveness to verbal and physical stimuli (unresponsive to sternal rub).
• Additional Signs: Cyanosis (bluish, grayish, or pale lips, fingernails, or skin), limp or flaccid muscles, clammy skin, and loud snoring or gurgling sounds (the "death rattle").

2. Proper Administration Technique

• Intranasal Formulation: Do not prime or test the device prior to administration (each unit contains exactly one single therapeutic dose; priming empties the medication). Insert the nozzle into one nostril until the fingers touch the base of the nose, and press the plunger firmly into the center of the cylinder.
• Repeat Dosing Timing: If the individual does not respond, wake up, or resume normal respiration within 2 to 3 minutes, administer a second dose using a brand-new device in the opposite nostril.

3. Critical Pharmacokinetics: The Recrudescence (Renarcotization) Danger

The single most critical warning a pharmacist must deliver during counseling concerns the pharmacokinetic disparity between naloxone and synthetic opioids:

• Naloxone Half-Life: Naloxone is rapidly metabolized, possessing a half-life of approximately 30 to 90 minutes, with clinical antagonist effects wearing off within 60 to 90 minutes.
• Opioid Half-Life: Long-acting or high-potency opioids (fentanyl, methadone, extended-release oxycodone, buprenorphine) have elimination half-lives lasting anywhere from 4 to 24+ hours.
• Renarcotization Risk: When the naloxone wears off, the opioid molecules remaining in the body will re-bind to the mu-opioid receptors, causing the patient to slip back into fatal respiratory arrest. This is why calling 911 is mandatory, even if the patient regains consciousness and insists they feel fine.

4. Management of Precipitated Acute Withdrawal

Naloxone immediately displaces opioids from receptor sites, precipitating abrupt and intense opioid withdrawal:

• Symptoms: Violent nausea, projectile vomiting, severe abdominal cramping, diaphoresis, piloerection ("goosebumps"), tachycardia, tremors, and intense psychomotor agitation.
• Aspiration Prevention: Because patients frequently vomit upon regaining consciousness, the patient must be placed in the recovery position (rolled onto their side) to prevent fatal aspiration of vomitus.